Table 2.
Base-case cost-effectiveness results of the bivalent, quadrivalent, and nonavalent HPV vaccination strategy: QALY, costs, and ICER
| Vaccination strategy | Total QALYs | Total costs (R) |
Compared with no vaccine | Compared with bivalent vaccine | ||||
|---|---|---|---|---|---|---|---|---|
| Δ QALYs | Δ Costs | ICER | Δ QALYs | Δ Costs | ICER | |||
| No vaccine | 25.16 | 30,805 | ||||||
| Bivalent | 25.31 | 19,265 | 0.15 | −11,540 | −77,115 | |||
| Quadrivalent | 25.29 | 20,013 | 0.13 | −9793 | −72,733 | −0.02 | 1748 | −116,397 |
| Nonavalent | 25.45 | 21,058 | 0.29 | −9747 | −33,908 | 0.14 | 1793 | 13,013 |
Costs are displayed in 2019 R
HPV human papillomavirus, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, R South African Rand